A BILL 
To amend the Public Health Service Act to provide for 
a demonstration program to facilitate the clinical adop-
tion of pregnancy intention screening initiatives by health 
care and social service providers. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Enhancing Questions 
4
to Understand Intentions for Pregnancy Act of 2020’’ or 
5
the ‘‘EQUIP Act of 2020’’. 
6
04:12 Mar 17, 2020
H6178
2 
•HR 6178 IH
SEC. 2. PREGNANCY INTENTION SCREENING INITIATIVE 
1
DEMONSTRATION PROGRAM. 
2
Part P of title III of the Public Health Service Act 
3
(42 U.S.C. 280g et seq.) is amended by adding at the end 
4
the following new section: 
5
‘‘SEC. 399V–7. PREGNANCY INTENTION SCREENING INITIA-
6
TIVE DEMONSTRATION PROGRAM. 
7
‘‘(a) PROGRAM ESTABLISHMENT.—The Secretary, 
8
through the Director of the Centers for Disease Control 
9
and Prevention, shall establish a demonstration program 
10
to facilitate the clinical adoption of pregnancy intention 
11
screening initiatives by health care and social service pro-
12
viders. 
13
‘‘(b) GRANTS.—The Secretary may carry out the 
14
demonstration program through awarding grants to eligi-
15
ble entities to implement pregnancy intention screening 
16
initiatives, collect data, and evaluate such initiatives. 
17
‘‘(c) ELIGIBLE ENTITIES.— 
18
‘‘(1) IN
GENERAL.—An eligible entity under 
19
this section is an entity described in paragraph (2) 
20
that provides non-directive, comprehensive, medically 
21
accurate information. 
22
‘‘(2) ENTITIES DESCRIBED.—For purposes of 
23
paragraph (1), an entity described in this paragraph 
24
is a community-based organization, voluntary health 
25
organization, public health department, community 
26
04:12 Mar 17, 2020
H6178
3 
•HR 6178 IH
health center, or other interested public or private 
1
primary, behavioral, or other health care or social 
2
service provider or organization. 
3
‘‘(d) PREGNANCY INTENTION SCREENING INITIA-
4
TIVE.—For purposes of this section, the term ‘pregnancy 
5
intention screening initiative’ means any initiative by an 
6
eligible entity to routinely screen women with respect to 
7
their pregnancy desires and goals to either prevent unin-
8
tended pregnancies or improve the likelihood of healthy 
9
pregnancies, in order to better provide health care that 
10
meets the contraceptive or pre-pregnancy needs and goals 
11
of such women. 
12
‘‘(e) EVALUATION.— 
13
‘‘(1) IN
GENERAL.—The Secretary, acting 
14
through the Director of the Centers for Disease 
15
Control and Prevention, shall, by grant or contract, 
16
and after consultation as described in paragraph (2), 
17
conduct an evaluation of the demonstration pro-
18
gram, with respect to pregnancy intention screening 
19
initiatives, conducted under this section. Such an 
20
evaluation shall include: 
21
‘‘(A) Assessment of the implementation of 
22
pregnancy intention screening protocols among 
23
a diverse group of patients and providers, in-
24
cluding collecting data on the experiences and 
25
04:12 Mar 17, 2020
H6178
4 
•HR 6178 IH
outcomes for diverse patient populations in a 
1
variety of clinical settings. 
2
‘‘(B) Analysis of outcome measures that 
3
will facilitate effective and widespread adoption 
4
of such protocols by health care providers for 
5
inquiring about and responding to pregnancy 
6
goals of women with both contraceptive and 
7
pre-pregnancy care. 
8
‘‘(C) Consideration of health disparities 
9
among the population served. 
10
‘‘(D) Assessment of the equitable and vol-
11
untary application of such initiatives to minor-
12
ity and medically underserved communities. 
13
‘‘(E) Assessment of the training, capacity, 
14
and ongoing technical assistance needed for 
15
providers to effectively implement such preg-
16
nancy intention screening protocols. 
17
‘‘(F) Assessment of whether referral sys-
18
tems for selected protocols follow evidence-based 
19
standards that ensure access to comprehensive 
20
health services and appropriate follow-up care. 
21
‘‘(G) Measuring through rigorous methods 
22
the effect of such initiatives on key health out-
23
comes. 
24
04:12 Mar 17, 2020
H6178
5 
•HR 6178 IH
‘‘(2) CONSULTATION WITH INDEPENDENT EX-
1
PERTS.—In conducting any evaluation under para-
2
graph (1), the Director of the Centers for Disease 
3
Control and Prevention shall consult with physi-
4
cians, physician assistants, advanced practice reg-
5
istered nurses, registered nurses, nurse midwives, 
6
and other health care providers who specialize in 
7
women’s health, and other experts in public health, 
8
clinical practice, program evaluation, and research. 
9
‘‘(3) REPORT.—Not later than one year after 
10
the last day of the demonstration program under 
11
this section, the Director of the Centers for Disease 
12
Control and Prevention shall submit to Congress a 
13
report on the results of the evaluation conducted 
14
under paragraph (1) and shall make the report pub-
15
licly available. 
16
‘‘(f) FUNDING.— 
17
‘‘(1) AUTHORIZATION
OF
APPROPRIATIONS.— 
18
To carry out this section, there is authorized to be 
19
appropriated $10,000,000 for each of fiscal years 
20
2021 through 2023. 
21
‘‘(2) LIMITATION.—Not more than 20 percent 
22
of funds appropriated to carry out this section pur-
23
suant to paragraph (1) for a fiscal year may be used 
24
04:12 Mar 17, 2020
H6178
6 
•HR 6178 IH
for purposes of the evaluation under subsection 
1
(e).’’. 
2
Æ 
04:12 Mar 17, 2020
H6178
